Thursday, February 09, 2023 7:47:44 PM
https://endpts.com/astrazeneca-snips-il-12-candidate-from-pipeline-as-it-sharpens-i-o-focus/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171170807
ATLnsider
sentiment _stocks, I agree with you. Also, in my opinion, I do not believe that the bears are reading past the first part of this section of the guidance. The second part of this guidance says the following:
If sponsors do not own the data used for the external control arm, they should structure their agreements with the data owners to ensure that patient-level data can be provided to FDA in support of the marketing application. Sponsors should also ensure that FDA has access to source documents and source data for the external control arm as part of an FDA inspection or upon request.
NWBio would not have direct access to the patient-level data because this data is owned by the Sponsors of these competing clinical trials. For proprietary reasons, and to potentially protect their IP, these Sponsors will not grant access to patient-level data to NWBio because they are a competitor or potential competitor, and these Sponsors were testing treatment options that would potentially compete with DCVax-L, such as: bevacizumab, rindopepimut, tumor-treating fields (TTF), ICT-107, etc.
However, because the FDA approved the IND and study protocol for all of these clinical trials, the FDA already has the right to access patient-level and raw data for all of these external control arms (ECAs) that NWBio used in both the nGBM and rGBM analysis.
Even though all of these other clinical trials failed (except for the TTF medical device Optune), the FDA already have the right to access patient-level and raw dataset. However, for confidentiality reasons, the FDA will not share this patient-level data with NWBio, but the FDA will use the patient-level data to validate the trial analysis results published by NWBio and Liau et al.
https://www.wsj.com/articles/pfizer-novartis-merck-executives-say-they-are-hunting-for-deals-again-11675907783
A comprehensive overview of the independent peer review is available at the link below. Explore all of the supplements attached to the JAMA publication and the podcast interview with Dr. Liau included on the JAMA Oncology website page for the murcidencel (DCVax-L) study.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
This video is about the P3 that was published in JAMA Oncology, but Dr. Toms also briefly mentions of the pembrolizumab combo study at UCLA at about timestamp 6:30. The PD1 combo study has reached its midpoint and the interim survival data are astonishing.
https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/
https://ceoworld.biz/2022/04/05/top-5-medical-journals-in-the-world-everyone-should-know-about/
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM